Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.

scientific article

Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/JCB.22933
P698PubMed publication ID21080343
P5875ResearchGate publication ID47795629

P50authorRenato FrancoQ37376215
Antonio RossiQ37829909
Michele CaragliaQ38321049
Ettore NovellinoQ38359645
Alessandro SgambatoQ39493156
Alfredo BudillonQ40122753
Mario MigaldiQ51621448
Agnese MolinariQ55779035
Giuseppina BozzutoQ58896092
Gerardo BottiQ62091425
P2093author name stringPaolo Grieco
Laura Toccacieli
Achille Cittadini
Monica Marra
Luigi Marra
Stefano Striano
Silvia Zappavigna
Luigi Gallo
P2860cites workHuman urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14Q22010575
Differential regulation of cell motility and invasion by FAKQ24673170
Genomic analysis of metastasis reveals an essential role for RhoCQ28144278
The focal adhesion kinase--a regulator of cell migration and invasionQ28202601
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysisQ29615193
Spatiotemporal dynamics of RhoA activity in migrating cellsQ29618433
MMP inhibition in prostate cancerQ33692934
Treatment decisions for localized prostate cancer: asking men what's importantQ33843865
Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular diseaseQ34204725
Urotensin-II receptor peptide agonistsQ35821444
Molecular markers of prostate cancer outcomeQ36088809
20-year outcomes following conservative management of clinically localized prostate cancerQ36115855
Rho signaling, ROCK and mDia1, in transformation, metastasis and invasionQ37374521
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cellsQ39837442
The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?Q40066264
Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell linesQ40341061
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trialQ40352912
Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II.Q40659791
Expression of endothelin-1 and endothelin receptors in cultured human glioblastoma cellsQ40842569
Effect of endothelin-1 as growth factor on a human glioma cell line; its characteristic promotion of DNA synthesisQ41586620
Urantide: an ultrapotent urotensin II antagonist peptide in the rat aortaQ41819007
Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious ratsQ43264253
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.Q44381567
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.Q51823933
Architecture of the Human Urotensin II Receptor: Comparison of the Binding Domains of Peptide and Non-Peptide Urotensin II AgonistsQ58855793
P433issue1
P921main subjectadenocarcinomaQ356033
prostate adenocarcinomaQ18555107
P304page(s)341-353
P577publication date2011-01-01
P1433published inJournal of Cellular BiochemistryQ6294917
P1476titleUrotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
P478volume112

Reverse relations

cites work (P2860)
Q42139903A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands
Q36800401Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER
Q39313143Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis.
Q90598614Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours
Q37582059Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma
Q88874237Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?
Q37740977Long non-coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR-1297.
Q48372089Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.
Q33599835The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features
Q34066190The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer
Q41613067Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients
Q33772333Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion
Q38588658Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer
Q39039151Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans.
Q92591557Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells

Search more.